Publications by Dr Celine Cano - ePrints

Browsing publications by Dr Celine Cano.

Newcastle Authors	Title	Year
Dr Celine Cano Professor Jane Endicott Dr Ian Hardcastle Dr Claire Jennings Suzanne Kyle et al.	Discovery of ASTX295, a potent, next-generation small molecule antagonist of MDM2 with differentiated pharmacokinetic profile	2024
Dr Elaine Willmore Suzanne Kyle Dr Yan Zhao Huw Thomas Dr Kenneth Rankin et al.	Targeting the MDM2-p53 interaction: Time- and concentration-dependent studies in tumor and normal human bone marrow cells reveal strategies for an enhanced therapeutic index	2024
Nikol Zografou Barredo Dr Alex Hallatt Dr Jennyfer Goujon-Ricci Dr Celine Cano	A beginner’s guide to current synthetic linker strategies towards VHL-recruiting PROTACs	2023
Duncan Miller Dr Suzannah Harnor Dr Mathew Martin Dr Richard Noble Professor Steve Wedge et al.	Modulation of ERK5 Activity as a Therapeutic Anti-Cancer Strategy	2023
Dr Suzannah Harnor Dr Celine Cano	Advanced approaches of developing targeted covalent drugs	2022
Gemma Davison Dr Mathew Martin Dr Shannon Turberville Selma Dormen Dr Richard Heath et al.	Mapping ligand interactions of bromodomains BRD4 and ATAD2 with FragLites and PepLites ─ Halogenated probes of druglike and peptide-like molecular interactions	2022
Duncan Miller Tristan Reuillon Dr Lauren Molyneux Dr Tim Blackburn Dr Noel Edwards et al.	Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor	2022
Islam Al-Khawaldeh Dr Christine Basmadjian Dr Cinzia Bordoni Dr Suzannah Harnor Amy Heptinstall et al.	An alkynylpyrimidine-based covalent inhibitor that targets a unique cysteine in NF-κB-inducing kinase (NIK)	2021
Edwige Picazo Amy Heptinstall Dr Celine Cano Emeritus Professor Bernard Golding Professor Mike Waring et al.	Cyclisations and fragmentations in the alkylation of 6-chloro-5-hydroxy-4-aminopyrimidines with aminoalkyl chlorides	2021
Dr Ian Hardcastle Dr Ruth Bawn Dr Tim Blackburn Dr Celine Cano Dr Sarah Cully et al.	Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction	2021
Christopher Matheson Christopher Coxon Dr Benoit Carbain Dr Ian Hardcastle Dr Suzannah Harnor et al.	2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase	2020
Dr Brian Ford Dr Shruti Chachra Ahmed Alshawi Alfie Brennan Dr Suzannah Harnor et al.	Chronic glucokinase activator treatment activates liver Carbohydrate response element binding protein and improves hepatocyte ATP homeostasis during substrate challenge	2020
Dr Celine Cano	Molecular dynamics simulations reveal the determinants of cyclin-dependent kinase 2 inhibition by 5-nitrosopyrimidine derivatives	2020
Dr Christine Basmadjian Dr Celine Cano	Nek7 conformational flexibility and inhibitor binding probed through protein engineering of the R-spine	2020
Dr Adam Potts Dr Celine Cano Professor Simon Thomas Dr Simon Hill	Synthetic cannabinoid receptor agonists: classification and nomenclature	2020
Daniel Wood Daniel Lopez Fernandez Leanne Knight Islam Al-Khawaldeh Dr Conghao Gai et al.	FragLites - minimal, halogenated fragments displaying pharmacophore doublets. An efficient approach to druggability assessment and hit generation	2019
Stephanie Myers Duncan Miller Dr Lauren Molyneux Dr Mercedeh Arasta Dr Ruth Bawn et al.	Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4	2019
Dr Catherine Willoughby Huw Thomas Dr Elaine Willmore Suzanne Kyle Dr Anita Wittner et al.	Selective DNA-PKcs Inhibition Extends the Therapeutic Index of Localized Radiotherapy and Chemotherapy	2019
Dr Simon Hill Dr Michael Dunn Dr Celine Cano Dr Suzannah Harnor Dr Ian Hardcastle et al.	Human Toxicity Caused by Indole and Indazole Carboxylate Synthetic Cannabinoid Receptor Agonists: From Horizon Scanning to Notification	2018
Duncan Miller Dr Mathew Martin Santosh Adhikari Alfie Brennan Professor Jane Endicott et al.	Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach	2018
Amy Heptinstall Dr Celine Cano Dr Ian Hardcastle	Recent advances in CDK inhibitors for cancer therapy	2018
Dr Celine Cano Dr Suzannah Harnor Dr Elaine Willmore Professor Steve Wedge	Targeting DNA-PK as a Therapeutic Approach in Oncology	2018
Judith Unterlass Dr Arnaud Basle Dr Julie Tucker Dr Celine Cano Professor Martin Noble et al.	Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer	2018
Christopher Coxon Dr Suzannah Harnor Dr Mathew Martin Dr Benoit Carbain Emeritus Professor Bernard Golding et al.	Cyclin-Dependent Kinase (CDK) Inhibitors; Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines	2017
Dr Suzannah Harnor Alfie Brennan Dr Celine Cano	Inhibition of the DNA-Dependent Protein Kinase for Cancer Therapy	2017
Professor David Rees Emeritus Professor Bernard Golding Dr Ian Hardcastle Dr Celine Cano Duncan Miller et al.	ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY	2017
Dr Suzannah Harnor James Pickles Dr Celine Cano	Modulation of the DNA-Damage Response by Inhibitors of the Phosphatidylinositol 3-Kinase Related Kinase (PIKK) Family	2017
Professor David Rees Emeritus Professor Bernard Golding Dr Ian Hardcastle Dr Celine Cano Duncan Miller et al.	Preparation of isoindolinones as inhibitors of the MDM2-p53 interaction having anticancer activity	2017
Professor David Rees Emeritus Professor Bernard Golding Dr Ian Hardcastle Dr Celine Cano Duncan Miller et al.	Preparation of isoindolinones as inhibitors of the MDM2-p53 interaction having anticancer activity;WO 2017055860	2017
Judith Unterlass Dr Arnaud Basle Dr Julie Tucker Dr Celine Cano Professor Martin Noble et al.	Structural insights into the enzymatic activity and potential substrate promiscuity of human 3-phosphoglycerate dehydrogenase (PHGDH)	2017
Dr Christopher Wong Dr Ian Hardcastle Christopher Matheson Professor Herbie Newell Dr Mangaleswaran Sivaprakasam et al.	Structure-guided design of purine-based probes for selective Nek2 inhibition	2017
Dr Suzannah Harnor Alfie Brennan Dr Celine Cano	Targeting DNA-Dependent Protein Kinase for Cancer Therapy	2017
Christopher Coxon Dr Celine Cano Emeritus Professor Bernard Golding Professor Roger Griffin	A new tool for the chemical genetic investigation of the Plasmodium falciparum Pfnek-2 NIMA-related kinase	2016
Dr Gary Beale Dr Emma Haagensen Huw Thomas Lan Wang Charlotte Revill et al.	Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo anti-tumour activity in colorectal cancer	2016
Dr Victorovich Zaytsev James Pickles Dr Suzannah Harnor Dr Alistair Henderson Mohammed Al Yasiri et al.	Concise syntheses of bridged morpholines	2016
Tristan Reuillon Dr Sari Alhasan Dr Gary Beale Annalisa Bertoli Alfie Brennan et al.	Design and synthesis of biphenyl and biphenyl ether inhibitors of sulfatases	2016
Stephanie Myers Dr Ruth Bawn Betty Cottyn Dr Lauren Molyneux Dr Celine Cano et al.	High-throughput screening and hit validation of extracellular-related kinase 5 (ERK5) inhibitors	2016
Tristan Reuillon Duncan Miller Stephanie Myers Dr Lauren Molyneux Dr Celine Cano et al.	Pyrrolcarboxamide Derivatives for the Inhibition of ERK5	2016
Emeritus Professor Bernard Golding Dr Celine Cano	Synthesis and Biological Evaluation of N²-Substituted 2,4-Diamino-6-cyclohexylmethoxy-5-nitrosopyrimidines and Related 5-Cyano-NNO-azoxy Derivatives as Cyclin-Dependent Kinase 2 (CDK2) Inhibitors	2016
Elisa Meschini Dr Regina Mora Vidal Dr Mathew Martin Dr Will Stanley Tristan Reuillon et al.	Identification and characterization of an irreversible inhibitor of CDK2	2015
Judith Unterlass Nabila Aljufri Sophie Bex Dr Celine Cano Professor Martin Noble et al.	Towards structure-based drug design of 3-phosphoglycerate dehydrogenase inhibitors	2015
Dr Benoit Carbain Dr Allyson Campbell Dr Celine Cano Professor Jane Endicott Emeritus Professor Bernard Golding et al.	8-Substituted O-6-Cyclohexylmethylguanine CDK2 Inhibitors: Using Structure-Based Inhibitor Design to Optimize an Alternative Binding Mode	2014
Honorine Lebraud Emeritus Professor Bernard Golding Elisa Meschini Dr Celine Cano Lan Wang et al.	Anticancer agents targeted against cyclin-dependent kinase 2 (CDK2): Structure-based design of irreversible and reversible inhibitors	2014
Dr Ruth Bawn Tristan Reuillon Emeritus Professor Bernard Golding Professor Roger Griffin Dr Ian Hardcastle et al.	Development of extracellular signal-regulated kinase 5 (ERK5) inhibitors for anti-cancer therapy	2014
Emily Mould Philip Berry Dr David Jamieson Dr Chris Hill Dr Celine Cano et al.	Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug activity	2014
Honorine Lebraud Christopher Coxon Vicky Archard Carlo Bawn Dr Benoit Carbain et al.	Model system for irreversible inhibition of Nek2: thiol addition to ethynylpurines and related substituted heterocycles	2014
Dr Susan Tudhope Dr Yan Zhao Dr Anita Wittner Annalisa Bertoli Santosh Adhikari et al.	Profiling inhibitors of MDM2: p53 and MDMX: p53 in relation to MDMX protein levels	2014
Dr Suzannah Harnor Dr Tommy Rennison Dr Martin Galler Dr Celine Cano Professor Roger Griffin et al.	Synthesis of 3 '-deoxy-3'-fluorothymidine (FLT) 5 '-O-glucuronide: a reference standard for imaging studies with [¹⁸F]FLT	2014
Dr Benoit Carbain Christopher Coxon Honorine Lebraud Dr Kris Elliott Christopher Matheson et al.	Trifluoroacetic Acid in 2,2,2-Trifluoroethanol Facilitates S_NAr Reactions of Heterocycles with Arylamines	2014
Annalisa Bertoli Santosh Adhikari Dr Suzannah Harnor Dr Yan Zhao Professor John Lunec et al.	Validation studies with small-molecule modulators of the MDM2/MDMX-p53 binding interaction	2014
Dr Celine Cano Dr Kappusamy Saravanan Professor Nicola Curtin Emeritus Professor Bernard Golding Dr Ian Hardcastle et al.	1-Substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones Endowed with Dual DNA-PK PI3-K Inhibitory Activity	2013
Dr Tommy Rennison Sonsoles Rodriguez-Aristegui Professor Nicola Curtin Emeritus Professor Bernard Golding Dr Ian Hardcastle et al.	Development of potent inhibitors of DNA-dependent protein kinase (DNA-PK)	2013
Sarah Cully Dr Celine Cano Emeritus Professor Bernard Golding Professor Roger Griffin Professor John Lunec et al.	Regiospecific synthesis of isoindolinones as MDM2 inhibitors	2013
Dr Celine Cano Professor Roger Griffin	The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug design	2013
Honorine Lebraud Dr Celine Cano Dr Benoit Carbain Dr Ian Hardcastle Dr Ross Harrington et al.	Trifluoroethanol solvent facilitates selective N-7 methylation of purines	2013
Dr Joanne Martin Michael Batey Dr Yan Zhao Dr Celine Cano Dr Michele Tavecchio et al.	Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K	2012
Dr Michele Tavecchio Dr Joanne Martin Dr Celine Cano Professor Herbie Newell Professor Nicola Curtin et al.	Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination	2012
Dr Tommy Rennison Faye Craven Emeritus Professor Bernard Golding Professor Roger Griffin Dr Karen Haggerty et al.	Potent enantioselective inhibition of DNA-dependent protein kinase (DNA-PK) by atropisomeric chromenone derivatives	2012
Dr Kate Smith Emeritus Professor Bernard Golding Elizabeth Griffin Professor Roger Griffin Dr Ian Hardcastle et al.	DNA-dependent protein kinase (DNA-PK) inhibitors: Structure–activity relationships for O-alkoxyphenylchromen-4-one probes of the ATP-binding domain	2011
Sonsoles Rodriguez-Aristegui Dr Lauren Molyneux Dr Celine Cano Dr Marine Desage-El-Murr Professor Roger Griffin et al.	Versatile Synthesis of Functionalised Dibenzothiophenes via Suzuki Coupling and Microwave-assisted Ring Closure	2011
Dr Celine Cano Emeritus Professor Bernard Golding Dr Karen Haggerty Dr Ian Hardcastle Professor Roger Griffin et al.	Atropisomeric 8-arylchromen-4-ones exhibit enantioselective inhibition of the DNA-dependent protein kinase (DNA-PK)	2010
Dr Kate Smith Dr Tommy Rennison Sonsoles Rodriguez-Aristegui Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Development of potent inhibitors of DNA-dependent protein kinase (DNA-PK)	2010
Dr Celine Cano Dr Olivier Barbeau Professor Nicola Curtin Emeritus Professor Bernard Golding Dr Ian Hardcastle et al.	DNA-Dependent Protein Kinase (DNA-PK) Inhibitors. Synthesis and Biological Activity of Quinolin-4-one and Pyridopyrimidin-4-one Surrogates for the Chromen-4-one Chemotype	2010
Sara Payne Sonsoles Rodriguez-Aristegui Dr Celine Cano Emeritus Professor Bernard Golding Dr Ian Hardcastle et al.	Mapping the ATP-binding domain of DNA-dependent protein kinase (DNA-PK) with coumarin- and isocoumarin-derived inhibitors	2010
Dr Benoit Carbain Dr Celine Roche Emeritus Professor Bernard Golding Dr Ian Hardcastle Dr Celine Cano et al.	Structure-based design of C8-substituted O6-alkylguanine CDK1 and 2 inhibitors	2010
Dr Francesco Marchetti Dr Celine Cano Professor Nicola Curtin Emeritus Professor Bernard Golding Professor Roger Griffin et al.	Synthesis and biological evaluation of 5-substituted O⁴-alkylpyrimidines as CDK2 inhibitors	2010
Dr Celine Cano Emeritus Professor Bernard Golding Dr Ian Hardcastle Professor Nicola Curtin Professor Roger Griffin et al.	8-Biarylchromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK)	2008
Dr Celine Cano Professor Nicola Curtin Emeritus Professor Bernard Golding Dr Karen Haggerty Dr Ian Hardcastle et al.	Development of Potent Water-soluble Inhibitors of DNA-Dependent Protein Kinase (DNA-PK)	2008
Dr Elaine Willmore Dr sarah Johnson Dr Tryfonia Mainou-Fowler Professor Graham Jackson Dr Celine Cano et al.	DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia	2008
Dr Celine Cano	Five-membered rings with two adjacent heteroatoms with at least one other element	2008
Dr Celine Cano	Five-membered rings with two non-adjacent heteroatoms with at least one other element	2008
Dr Kappusamy Saravanan Dr Celine Cano Professor Nicola Curtin Emeritus Professor Bernard Golding Dr Karen Haggerty et al.	Identification of potent water-soluble DNA-dependent protein kinase (DNA-PK) inhibitors using a small-molecule library approach [abstract]	2008
Jonathan Hollick Dr Laurent Rigoreau Dr Celine Cano Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase	2007
Dr Olivier Barbeau Dr Celine Cano Professor Roger Griffin Dr Ian Hardcastle Professor William Clegg et al.	Quinolinone and pyridopyrimidinone inhibitors of DNA-dependent protein kinase	2007
Dr Celine Cano	A bis(η5-cyclopentadienyl)cobalt complex of a bis-dithiolene: a chemical analogue of the metal centres of the DMSO reductase family of molybdenum and tungsten enzymes, in particular ferredoxin aldehyde oxidoreductase	2005
Dr Celine Cano	Regio- and Enantioselective Synthesis of Novel Functionalized Pyranopyrrolidines by 1,3-Dipolar Cycloaddition of Carbohydrates	2005
Dr Celine Cano	Stereoselective Cycloaddition on Carbohydrates for the Synthesis of New Bicyclic Oxazolidines Bearing a Quaternary Bridgehead	2005